Tesamorelin
Also known as Tesamorelin acetate, GHRH(1-44), TH9507, Somatoliberin (modified)
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary to release its own growth hormone, achieving FDA-approved clinical efficacy for HIV-associated lipodystrophy with 15-20% visceral adipose tissue (VAT) reduction over 26 weeks—preferentially targeting dangerous abdominal fat while preserving subcutaneous fat and lean muscle mass, a metabolic selectivity unique among weight loss therapies.
Route
Subcutaneous injection
Dose range
1 mg – 2 mg
Frequency
Once per day (subcutaneous), preferably in the evening
Cycle length
12–26 weeks

Tesamorelin 10mg
Third-party tested, lot traceable, ships in 3–5 business days.
Overview
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary to release its own growth hormone, achieving FDA-approved clinical efficacy for HIV-associated lipodystrophy with 15-20% visceral adipose tissue (VAT) reduction over 26 weeks—preferentially targeting dangerous abdominal fat while preserving subcutaneous fat and lean muscle mass, a metabolic selectivity unique among weight loss therapies.
The physiologic mechanism (pulsatile GH stimulation) avoids the feedback suppression and side effects of direct HGH therapy while raising IGF-1 levels 30-50%, supporting muscle preservation, bone density, collagen synthesis, and metabolic health. Clinical research demonstrates 37% hepatic steatosis reduction alongside VAT loss, making it valuable for fatty liver disease progression prevention. Unlike appetite suppressants causing global weight loss, Tesamorelin selectively mobilizes visceral fat through metabolic reprrogramming, with benefits persisting weeks after discontinuation. For individuals with dangerous abdominal obesity, metabolic syndrome, or fatty liver disease, Tesamorelin offers pharmaceutical-grade visceral fat targeting with lean preservation.
Studied benefits
- Effectively reduces visceral (abdominal) fat and may improve lipid profiles
- There is also emerging research regarding its potential to enhance cognitive function in older adults
Reported side effects
- Common side effects include joint pain, muscle aches, and mild swelling (edema)
- It may also lead to "carpal tunnel-like" symptoms (tingling in hands) and requires monitoring of blood sugar (HbA1c) and IGF-1 levels
- Contraindicated in those with active malignancies
Protocol
Dosing Schedule (Subcutaneous)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
Tesamorelin (5mg)
Reconstitute with 2.5 mL bacteriostatic water (Final concentration: 2.0 mg/mL).
Reduce visceral adipose tissue and improve lipid profiles through sustained GH/IGF-1 elevation.
Tesamorelin (10mg)
Reconstitute with 3.0 mL bacteriostatic water (Final concentration: ~3.33 mg/mL).
Reduce visceral adipose tissue and improve lipid profiles through sustained GH/IGF-1 elevation.
Tesamorelin (20mg)
Reconstitute with 3.0 mL bacteriostatic water (Final concentration: ~6.67 mg/mL).
Reduce visceral adipose tissue and improve lipid profiles through sustained GH/IGF-1 elevation.
| Week | Daily Dose (mg / mcg) | Draw at 2 mg/mL | Log |
|---|---|---|---|
| Week 1 | 1 mg / 1000 mcg | 50 units (0.5 mL) | + Log |
| Weeks 2–12+ | 2 mg / 2000 mcg | 100 units (1 mL) | + Log |
Frequency
Once per day (subcutaneous), preferably in the evening.
Timing
Evening administration; rotate sites to reduce local irritation.
Cycle length
12–26 weeks.
Unit calculator
Set your vial and water; the table above updates.
2 mg/mL
5 doses of 1 mg per vial
At the starting dose (1 mg × 7/week for a 12-week cycle) you would use about 84 mg, i.e. 17 × 5 mg vials. Higher phases use proportionally more.
Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.
Context
Lifestyle considerations
Follow a nutrient-dense, protein-forward diet while maintaining a slight caloric deficit if the primary goal is the reduction of visceral fat, a key focus of this Growth Hormone Releasing Hormone (GHRH) analog. Incorporate regular cardiovascular activity and strength training to capitalize on the peptide’s ability to improve lean muscle mass and metabolic health markers. Ensure 7–9 hours of quality sleep, as the peptide acts to increase the amplitude of natural growth hormone pulses during the nocturnal cycle. Monitor blood glucose levels periodically, as sustained GH elevation can occasionally impact insulin sensitivity in certain research subjects.
Evidence
Research summaries
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials
Findings: Shrinks belly fat 24% in 6 months, lowers triglycerides and cholesterol, improves how people feel about their body, safe on blood sugar.
806 HIV patients on meds got daily Tesamorelin 2mg or placebo shots. After 26 weeks, belly fat dropped 24% (versus plus 2% for placebo), with triglycerides down 37 mg/dL vs slight rise for others. Cholesterol and belly appearance both improved big-time. A year in, fat loss held steady at 17.5% below baseline, waist thinner by 3.4 cm. Regular under-skin fat stayed same—only deep dangerous fat melted. IGF-1 (the growth signal) jumped 108 ng/mL. Body image scores surged; men felt way better. Blood sugar stayed normal, no serious side effects beyond mild shot site reactions. This proves Tesamorelin's power for HIV lipodystrophy, improving looks and heart health long-term.
Read the study ↗Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation
Findings: Keeps belly fat off for a full year, maintains muscle and strength, steadies good cholesterol and blood fats.
After 26 weeks of work, 410 HIV patients kept going or switched to Tesamorelin for 26 more weeks. Those staying on it held their 18% belly fat loss strong at 52 weeks (35 cm² down). Triglycerides stayed dropped 51 mg/dL below start. Total cholesterol held lower. Glucose stayed stable—no diabetes risk even long-term. When patients quit, belly fat came back, proving the medicine keeps working while used but isn't permanent (like exercise). Safe profile matched first 6 months. For HIV folks stuck with extra gut weight, this shows Tesamorelin is a trusty, consistent fix for 12 months, reshaping body safely.
Read the study ↗Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity
Findings: Shrinks waist, boosts growth hormone (IGF-1), improves thinking and mood hints in HIV brain fog.
73 HIV patients with fuzzy thinking and big bellies took Tesamorelin 2mg daily or standard care for 6 months. Waist shrank 2.7 cm more with Tesamorelin; IGF-1 spiked, fueling cells. Thinking test scores trended better (+0.146 vs +0.103 for care-as-usual), but gap missed significance—likely study too small. Brain fog from belly fat and low growth hormone improved subtly, hinting at deeper brain benefits. Daily injection simple. Safe—no odd side hits. Shows Tesamorelin's promise beyond just fat loss, touching brain health tied to obesity in HIV survivors.
Read the study ↗Tesamorelin improves fat quality independent of changes in visceral adiposity (muscle quality and composition effects)
Findings: Tones abdominal muscles, fills rectus/core lean tissue, strengthens trunk even without extra fat loss.
CT scans of 341 HIV patients on Tesamorelin showed core muscles got denser and firmer—rectus belly muscle jumped 4.86 Hounsfield units (density boost). Lean meat in abs, flanks, lower back all thickened. Muscle fat decreased separately from belly fat drop, meaning peptide rebuilds tone. Abs looked carved, waist lines sharper. Effects held even after adjusting for IGF-1 spikes, proving local muscle tighten. Perfect for folks wanting sculpted cores, not just thin bellies—Tesamorelin delivers gym-like toning via hormone magic. Tesamorelin research spotlights belly-fat buster for HIV. Visceral fat melts 24%, muscle tones, cholesterol drops, mood lifts—safe a full year and beyond. Tesamorelin stands out as a synthetic growth hormone-releasing hormone (GHRH) analog specifically engineered to combat visceral adipose tissue (VAT) accumulation, particularly in HIV patients experiencing lipodystrophy from antiretroviral therapy. By binding to pituitary GHRH receptors, it triggers pulsatile endogenous growth hormone (GH) secretion, e
Read the study ↗More references (4)
Identification
Chemistry
- common names
- Tesamorelin, Tesamorelin acetate, Growth Hormone-Releasing Hormone (1-44) amide, GHRH(1-44), TH9507, Somatoliberin (modified)
- cas
- 218949-48-5 (free base); 901758-09-6 (acetate salt)
- molecular weight
- 5135.86 Da (free base); approximately 5579 Da (acetate salt with ~7.4 acetate counter ions per molecule)
- source
- Synthetic; derived from human GHRH sequence but not naturally occurring
- biosynthesis
- Nonribosomal synthetic peptide manufactured by solid-phase peptide synthesis
- type
- Linear 44-amino acid peptide chain, amidated at C-terminus
Keep exploring
Related peptides
5-Amino-1MQ
5-amino-1-methylquinolinium · NNMTi
- Route
- Subcutaneous
- Dose
- 2.5 mg – 5 mg
- Cycle
- 10–20 days (based on a single 50 mg vial)
Adipotide (FTPP)
FTPP · Adipotide
- Route
- Subcutaneous
- Dose
- 5 mcg – 20 mcg
- Cycle
- 21–28 days; monitoring of renal markers is standard
AICAR
Acadesine · AICA-Riboside
- Route
- Subcutaneous
- Dose
- 1 mg – 3 mg
- Cycle
- 8–12 weeks
AOD-9604
AOD 9604 · Tyr-hGH fragment 177-191
- Route
- Subcutaneous
- Dose
- 200 mcg – 500 mcg
- Cycle
- 8–12 weeks